Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Adv Drug Deliv Rev. 2021 May 29;175:113803. doi: 10.1016/j.addr.2021.05.013

Figure 8. Combination delivery approaches resulting in synergic efficacy.

Figure 8.

(A) Combination of TLR7 agonist (R837) and TLR4 agonist (MPLA) encapsulated in PLGA particles synergistically improves antibody responses against H5N1-influenza-derived HA. (B) A single molecule containing TLR7 agonist (loxoribine), TLR4 agonist (pyrimido-indole) and TLR9 agonist (CpG ODN) improves antibody responses compared to the admixed formulation of the three agonists. (C) Combination of TLR7/8 agonist (R848) and anti-OX40 antibody demonstrates synergistic anti-tumor effects in A20 B cell lymphoma mouse model.